NCT07522905

Virtual Buddy Movement Therapy for Psychomotor and Social Development in Pediatric Oncology Patients in Remission

Not yet recruiting NA Last updated 15 April 2026

What this trial tests

NA trial testing Virtual BUDDY-Movement Therapy in Precursor Cell Lymphoblastic Leukemia-Lymphoma in 40 participants. Not yet recruiting.

Timeline

7 April 2026

Primary endpoint
31 December 2026

31 December 2027

Quick facts

Lead sponsor	Comenius University
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	40
Start date	7 April 2026
Primary completion	31 December 2026
Estimated completion	31 December 2027

Drugs / interventions tested

• Virtual BUDDY-Movement Therapy

Conditions studied

• Precursor Cell Lymphoblastic Leukemia-Lymphoma — all drugs for Precursor Cell Lymphoblastic Leukemia-Lymphoma →

Sponsor

Comenius University

Who can join

Adults 5 to 12, any sex, with Precursor Cell Lymphoblastic Leukemia-Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Acute lymphoblastic leukemia is the most common type of cancer in children diagnosed between the ages of two and five. After cancer treatment, children suffer from fatigue and exhaustion, and thus a decrease in daily physical activity. In addition, lack of physical activity and sports causes a decrease in strength and mobility and affects coordination of movements, proprioceptive perception and balance, which can lead to the occurrence of many injuries. In addition, physical inactivity in children who have survived cancer increases the risk of cardiovascular diseases or causes overweight and obesity. In addition, the separation of children with cancer from their peers harms social, emotional, physical and school indicators of quality of life. The aim of the project is to determine the impact of 12 weeks of buddy-movement therapy on the psychomotor and social development of pediatric cancer patients in remission. The investigators expect a significant improvement in the motor skills of pediatric oncology patients in remission, specifically in fine and gross motor skills, in coordination of both hands, in body coordination, in strength and dexterity. The investigators also assume that after the introduction of 12-week buddy-movement therapy, there will be a significant improvement in the quality of life of pediatric oncology patients in remission, specifically in emotional functioning, in social functioning, in physical functioning and in school functioning. Furthermore, it is anticipated that after the introduction of 12-week buddy-movement therapy, the study will notice significant differences in motor skills between the experimental and control groups. It is also assumed that after the introduction of 12-week buddy-movement therapy, significant differences in quality of life between the experimental and control groups will be observed. The research will involve pediatric oncology patients in remission aged 5 to 12 years with acute lymphoblastic leukemia - ALL, who are treated at the Department of Pediatric Hematology and Oncology of the National Institute of Children's Diseases (NÚDCH). The research participants will undergo an entry and exit examination, including body mass index (BMI; kg/m\^2) calculated from weight (kg), height (m), waist circumference (cm), hip circumference (cm), psychomotor examination using the Bruininks-Oseretsky Test of Motor Proficiency, Second Edition, and quality of life measured by the Pediatric Quality of Life Inventory. They will be divided into a control and experimental group, with the experimental group undergoing a 12-week Buddy-movement therapy focused on the development of psychomotor skills and socialization of participants using Buddy peer support.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.